Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.
*Author to whom correspondence should be addressed.
Acute myeloid leukaemia (AML) is a heterogeneous disease covering a range of morphological lineages and differentiation stages, but also has number of recurrent chromosomal abnormalities and mutations associated with prognosis. Because of the defined molecular and cytogenetic features, AML has been a focus of gene expression profiling studies and identified differentially expressed genes in the different diagnostic and cytogenetic sub-groups. These studies have lead to the development of expression based classifications and diagnostic chips with further studies aiding prognosis and therapeutic choices.